1. Pink Sheet

UK Avoids 'Cliff Edge' By Extending EU Drug Approval Reliance Procedure

 
• By Ian Schofield

The UK drugs regulator says it needs to make sure that companies do not “deprioritize” GB approval applications while a new “international reliance framework” is being developed.

Plenty of capsules and pills laying on a flag of Great Britain
The UK MHRA will continue to allow reliance on EU drug approvals for another year • Source: Shutterstock

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has extended by one year the streamlined procedure that allows pharmaceutical companies to gain faster Great Britain marketing authorizations based on approval recommendations made by the European Medicines Agency.

The European Commission Decision Reliance Procedure (ECDRP) was introduced in response to concerns that after Brexit, companies might delay new drug submissions to the MHRA in favor of an EU

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet

EU Shaping Biotech Act To Unleash SME Potential

 
• By Neena Brizmohun

European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.

New EU Filings

 
• By Neena Brizmohun

Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.